Mode
Text Size
Log in / Sign up
Phase 2 N=746 Randomized Treatment

Gradual vs. Abrupt Cessation Treatment for Smoking

Smoking Cessation

Enrolled (actual)
746
Serious AEs
0.0%
Results posted
Sep 2012
Primary outcome: Primary: Number of Participants With Prolonged Abstinence Through 6 Months Verified by Carbon Monoxide Measurement — 12; 20; 7 participants — p=0.30

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Reduction Phone Counseling (Behavioral); Abrupt Phone Counseling (Behavioral); Minimal Abrupt Phone Counseling (Behavioral); Pre-Quit Nicotine Lozenges (Drug); Post-Quit Nicotine Lozenges (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Vermont
Primary completion
Feb 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Prolonged Abstinence Through 6 Months Verified by Carbon Monoxide Measurement
12; 20; 7 0.30

Summary

This study tests whether stopping smoking by gradually cutting down first is more or less successful than stopping abruptly. We hypothesize that stopping by gradually cutting down first will produce more abstinence than stopping abruptly.

Eligibility Criteria

Inclusion Criteria

  • Interested in quitting gradually
  • At least 18 years old
  • Daily cigarette smoker
  • Smoke at least 15 cigarettes per day (CPD)
  • No change greater than 20% in CPD in the last month
  • Interested in quitting in next 30 days
  • Must agree to not use non-cigarette tobacco during study
  • No use of smoking cessation medication in last month
  • Have phone with voice mail
  • Willing to use nicotine lozenge
  • No other person in household in study
  • Fluent/literate in English

Exclusion Criteria

  • Women who are pregnant or breastfeeding
  • Currently using medication for depression or asthma
  • Heart disease requiring medication
  • Heart attack in last month
  • Irregular heartbeat
  • High blood pressure not controlled by medication
  • Stomach ulcers
  • Diabetes
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00297492). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search